📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Huyabio

1.1 - Company Overview

Huyabio Logo

Huyabio

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of novel biopharmaceutical product opportunities, including HBI-8000, an oral class I selective HDAC inhibitor for cancers; HBI-3000, a multi-ion channel blocker for atrial fibrillation; HBI-2376, an SHP2 inhibitor for solid tumors; HBI-ONC, an epigenetic inhibitor for MDS/AML; and HBI-3800, a small molecule to regenerate cardiac muscle damaged by ischemia.

Products and services

  • HBI-2376: An immune-modulatory SHP2 inhibitor engineered to target solid tumors, including EGFR/KRAS mutant cancers, demonstrating efficacy in combination with other cancer therapies
  • HBI-8000: A class I selective histone deacetylase inhibitor developed to treat lymphomas and melanomas by altering histone structure and modulating tumor immunity
  • HBI-ONC: An epigenetic inhibitor produced for myelodysplastic syndrome and acute myeloid leukemia, leveraging epigenetic drug expertise for hematologic cancer applications

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Huyabio

Foldax Logo

Foldax

HQ: United States Website
  • Description: Provider of synthetic heart valve solutions delivering non-thrombogenic aortic and mitral valves at lower cost, including TRIA surgical and TAVR valves with computer-designed frames and leaflets to match natural function; LifePolymer non-animal polymer offering biostability, biocompatibility and resistance to calcification; automated robotic manufacturing, FEA design, and polymer applications in medical and industrial devices.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Foldax company profile →
WR Medical Logo

WR Medical

HQ: United States Website
  • Description: Provider of medical devices.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full WR Medical company profile →
TriVascular Logo

TriVascular

HQ: United States Website
  • Description: Provider of new medical devices delivering optimal solutions for endovascular aortic repair (EVAR).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full TriVascular company profile →
Caliber Therapeutics Logo

Caliber Therapeutics

HQ: United States Website
  • Description: Provider of stent-free targeted angioplasty drug delivery solutions, featuring the Virtue Sirolimus AngioInfusion Balloon, an investigational drug/device delivering extended-release sirolimus during balloon angioplasty without coating or permanent implant, and BackBeat Cardiac Neuromodulation Therapy, an investigational bioelectronic treatment for hypertension that modulates autonomic nervous system responses.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Caliber Therapeutics company profile →
Corimmun Logo

Corimmun

HQ: Germany Website
  • Description: Provider of novel therapeutics and diagnostics for heart and vascular diseases. A clinical drug development company based in Martinsried near Munich, Germany, Corimmun spans the full spectrum from research to drug development and commercialization.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Corimmun company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Huyabio

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Huyabio

2.2 - Growth funds investing in similar companies to Huyabio

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Huyabio

4.2 - Public trading comparable groups for Huyabio

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Huyabio

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Huyabio

What does Huyabio do?

Huyabio is a provider of novel biopharmaceutical product opportunities, including HBI-8000, an oral class I selective HDAC inhibitor for cancers; HBI-3000, a multi-ion channel blocker for atrial fibrillation; HBI-2376, an SHP2 inhibitor for solid tumors; HBI-ONC, an epigenetic inhibitor for MDS/AML; and HBI-3800, a small molecule to regenerate cardiac muscle damaged by ischemia.

Who are Huyabio's competitors?

Huyabio's competitors and similar companies include Foldax, WR Medical, TriVascular, Caliber Therapeutics, and Corimmun.

Where is Huyabio headquartered?

Huyabio is headquartered in United States.

How many employees does Huyabio have?

Huyabio has 1,000 employees 🔒.

When was Huyabio founded?

Huyabio was founded in 2010 🔒.

What sector and industry vertical is Huyabio in?

Huyabio is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Huyabio

Who are the top strategic acquirers in Huyabio's sector and industry

Top strategic M&A buyers and acquirers in Huyabio's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Huyabio?

Top strategic M&A buyers groups and sectors for Huyabio include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Huyabio's sector and industry vertical

Which are the top PE firms investing in Huyabio's sector and industry vertical?

Top PE firms investing in Huyabio's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Huyabio's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Huyabio's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Huyabio's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Huyabio include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Huyabio's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Huyabio?

The key public trading comparables and valuation benchmarks for Huyabio include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Huyabio for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Huyabio with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Huyabio's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Huyabio with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Huyabio's' sector and industry vertical?

Access recent funding rounds and capital raises in Huyabio's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Huyabio